Abstract 3448: The IV STING agonist, TAK-676, enhances immune-mediated anti-tumor activity of radiation in syngeneic mouse models
Appleman, Vicky A., Berger, Allison J., Roberts, Emily R., Maldonado-Lopez, Angel E., Ganno, Michelle L., Christensen, Camilla I., Hatten, Tiquella, Sato, Yosuke, Shaw, Michael H., Malek, Karim S., Lineberry, Neil B., Abu-Yousif, Adnan O., Gregory, Richard C.
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Get full text
Journal Article
Abstract 1841: TAK-500 is a clinical stage immune-cell directed antibody drug conjugate (iADC) inducing STING activation in CCR2-expressing intratumor myeloid cells and favorable immunomodulation
Schalper, Kurt A., Matsuda, Atsushi, Ganno-Sherwood, Michelle, Maldonado-Lopez, Angel E., Rosentrater, Emily, Porciuncula, Angelo, Zhang, Dong Mei, Christensen, Camilla L., Merrigan, Samantha A., Hatten, Tiquella, Lee, Hong Myung, Lee, Min Young, Dong, Linlin, Huang, Jian, Iartchouk, Natasha, Wang, Jianing, Xu, He, Yoneyama, Tomoki, Piatkov, Konstantin I., Harbison, Carole E., Parent, Alex, Lineberry, Neil, Abu-Yousif, Adnan O., Appleman, Vicky
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Get full text
Journal Article